Danavorexton (TAK-925): an orexin receptor 2 agonist as a new ‘arousal’ agent
Version 2 2025-02-04, 16:06Version 2 2025-02-04, 16:06
Version 1 2025-01-29, 16:09Version 1 2025-01-29, 16:09
journal contribution
posted on 2025-02-04, 16:06authored byDavid G Lambert, Kazuyoshi Hirota
A preclinical study in animals has further characterised a new ‘arousal’ agent. Danavorexton (TAK-925) is an agonist for orexin receptor 2 where it promotes recovery from inhalational and i.v. anaesthesia and opioid sedation. Although danavorexton reverses opioid sedation, it does not compromise analgesia. This could be a useful addition to the postoperative drug cupboard.